Cornerstone Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cary NC United States (2003)
Status: Acquired by Chiesi (2014)

Organization Overview

First Clinical Trial
2013
NCT01805687
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cornerstone Therapeutics Inc.

Active Ingredients

Drugs in Phase 4 Trials (4)

Key: Cornerstone Therapeutics (0) Acquired (4)

labetalol (trandate) (1 trial)

morphine (4 trials)

nicardipine (cardene) (1 trial)

zileuton (zyflo) (5 trials)

Drugs in Phase 3 Trials (1)

Key: Cornerstone Therapeutics (0) Acquired (1)

lixivaptan (6 trials)

Drugs in Phase 2 Trials (1)

Key: Cornerstone Therapeutics (0) Acquired (1)

pyruvate (1 trial)

Drugs in Phase 1 Trials (1)

Key: Cornerstone Therapeutics (0) Acquired (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Overview

  • Highest Phase: None
  • # of Trials: 17
  • # of Trial APIs: 7